Open AccessCost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
Author(s) -
Yamin Shu,
Qilin Zhang,
XuCheng He,
Li Chen
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s334643
Subject(s) - gefitinib , medicine , lung cancer , oncology , epidermal growth factor receptor , chemotherapy , cost effectiveness , cost effectiveness analysis , quality adjusted life year , cancer , risk analysis (engineering)